Summary
Some T cell-dependent immune parameters were examined in mice bearing a large MOPC-315 plasmacytoma before and after treatment with a low dose (15 mg/kg) of CY. Prior to CY therapy, spleen cells from mice bearing a large MOPC-315 tumor were depressed in their ability to generate an in vitro cytotoxic response to the MOPC-315 tumor, to a different syngeneic plasmacytoma, MOPC-104E, and to an allogeneic thymoma, EL4. The spleen cells of these mice were also depressed in their ability to proliferate in response to the T cell mitogen PHA. Following CY therapy, the spleen cells generated an enhanced anti-MOPC-315 cytotoxic response by day 2, and the level of this response continued to increase so that by day 7, it was greatly enhanced and was much greater than the response of normal spleen cells. The recovery of the cytotoxic responsiveness to the antigenically related MOPC-104E tumor after CY therapy followed a similar pattern. In contrast, the spleen cells of these animals remained depressed in their cytotoxic response to the antigenically unrelated EL4 thymoma for at least 11 days after CY therapy. Although the anti-EL4 response recovered by day 14, the level of antitumor cytotoxicity generated did not exceed that generated by normal spleen cells. The PHA response remained greatly depressed in CY-treated MOPC-315 tumor bearers, even 14 days after the chemotherapy. Thus, at a time following low-dose CY therapy, when potent T cell-dependent antiplasmacytoma immunity had completed the eradication of a large MOPC-315 tumor burden not eliminated through the direct effect of the drug, the T cell-dependent response to an unrelated tumor and to PHA remained depressed.
Similar content being viewed by others
References
Berd D, Maguire HC, Mastangelo MJ (1986) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46:2572
Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10
Brandes LJ, Israels LG (1982) Treatment of advanced plasma cell myeloma with weekly cyclophosphamide and alternate-day prednisone. Cancer Treat Rep 66:1413
Burton RC, Warner NL (1977) Tumor immunity to murine plasma cell tumors. III. Detection of common and unique antigens on BALB/c, C3H, and NZB plasmacytomas by in vivo and in vitro induction of tumor-immune-responses. J Natl Cancer Inst 58:701
Burton RC, Thompson J, Warner NL (1975) In vitro induction of tumor specific immunity. J Immunol Methods 8:133
Chang ZL, Wang J, Wang QD, Liu KL, Yao Z (1980) Activation of adherent suppressor macrophages in spleens of mice bearing Ehrlich solid tumor. Acta Biol Exp Sin 13:155
Hande KR, Oldham RK, Fer MF (1982) Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer. Am J Med 73:413
Hengst JCD, Mokyr MB, Dray S (1980) Importance of timing in cyclophosphamide therapy of MOPC-315 tumor bearing mice. Cancer Res 40:2135
Hengst JCD, Mokyr MB, Dray S (1981) Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res 41:2163
Ly IA, Mishell RI (1974) Separation of mouse spleen cells by passage through columns of Sephadex G-10. J Immunol Methods 5:239
Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC (1988) Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 6:409
Mokyr MB, Barker E (1986) Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers. Cancer Immunol Immunother 23:11
Mokyr MB, Dray S (1983) Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low rather than a high dose of cyclophosphamide. Cancer Res 43:3112
Mokyr MB, Braun DP, Usher D, Reiter H, Dray S (1978) The development of in vitro and in vivo anti-tumor cytotoxicity in non-cytotoxic MOPC-315 tumor-bearer spleen cells “educated” in vitro with MOPC-315 tumor cells. Cancer Immunol Immunother 4:143
Mokyr MB, Braun DP, Dray S (1979) Augmentation of antitumor cytotoxicity in MOPC-315 tumor-bearer spleen cells by depletion of glass-adherent cells prior to in vitro activation. Cancer Res 39:785
Mokyr MB, Hengst JCD, Dray S (1982) Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors. Cancer Res 42:974
Mokyr MB, Colvin M, Dray S (1984) Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor. Int J Immunopharmacol 7:111
Nikcevich DA, Duffie GD, Young MR, Ellis NK, Kaufman GE, Wepsic HT (1987) Stimulation of suppressor cells in the bone marrow and spleen of high-dose cyclophosphamide treated C57BL/6 mice. Cell Immunol 109:349
Okada M, Henney CS (1980) The differentiation of cytotoxic T cells in vitro III. The role of helper T cells and their products in the differentiation of cytotoxic cells from “memory” cell populations. J Immunol 125:850
Samson MK, Rivkin SE, Jones SE (1984) Dose-response and dose-survival advantage for high-versus low-dose cisplatin with vinblastine and bleomycin in disseminated testicular cancer. A southwest oncology group study. Cancer 53:1029
Segre M, Tomei E, Segre D (1985) Cyclophosphamide-induced suppressor cells in mice: suppression of the antibody response in vitro and characterization of the effector cells. Cell Immunol 91:443
Spreafico F, Anacierico A (1977) Immunosuppressive agents. In: Hadden J, Coffey RG, Spreafico F (eds) Comprehensive immunology, volume 3, immunopharmacology. Plenum Medical Book Co, New York, p 259
Takesue BY, Bartik MM, Mokyr MB (1987) Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt-2 and L3T4 antigens. Int J Immunopharmacol 9:705
Tilly H, Castaigne S, Bordessoule D (1985) Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients. Cancer 55:1633
Ye Q-W, Mokyr MB (1985) Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor. Cancer Res 44:3873
Ye Q-W, Mokyr MB, Pyle JM, Dray S (1984) Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 16:162
Author information
Authors and Affiliations
Additional information
Supported by United Public Health Service Research Grant #CA-30088 and by Training Grant #CA-09318 from the National Cancer Institute
In partial fulfillment of the requirements of the Graduate College for the Doctor of Philosophy degree
Abbreviations used: CY, cyclophosphamide; FBS, fetal bovine serum; FITC, fluorescein isothiocyanate; PHA, phytohemagglutinin
Rights and permissions
About this article
Cite this article
Wise, J.A., Mokyr, M.B. & Dray, S. Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas. Cancer Immunol Immunother 27, 191–197 (1988). https://doi.org/10.1007/BF00205439
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00205439